As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
16 Analysts have issued a Aquestive Therapeutics, Inc. forecast:
16 Analysts have issued a Aquestive Therapeutics, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 43 43 |
26%
26%
|
|
| Gross Profit | 26 26 |
36%
36%
|
|
| EBITDA | -56 -56 |
177%
177%
|
|
| EBIT (Operating Income) EBIT | -56 -56 |
166%
166%
|
|
| Net Profit | -69 -69 |
93%
93%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
| Head office | United States |
| CEO | Daniel Barber |
| Employees | 142 |
| Founded | 2004 |
| Website | aquestive.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


